Skip to main content
Fig. 4 | BMC Immunology

Fig. 4

From: Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells

Fig. 4

Anti-CEA-CAR NK-92MI recognise and kill CEA-expressing cells. Cytotoxicity of parental NK-92MI () or anti-CEA-CAR NK-92MI () against (a) human K562 erythroleukemia cells, (b) low-CEA-expressing HCT116 cells, (c) mildly CEA-expressing WiDr cells, and (d) highly CEA-expressing LS174T cells. Cells were incubated either with parental or anti-CEA-CAR NK-92MI at various effector/target (E/T) ratios for 4 h. Tumour lysis was determined from the release of LDH and measured by CytoTox96® non-radioactive cytotoxicity assay. Representative data from experiments conducted independently in triplicate are shown. *P <  0.05

Back to article page